Study: Most nononcology accelerated approval pivotal trials use surrogate endpoints
Regulatory NewsJeff Craven
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesExpedited pathwaysPharmaceuticalsProduct LifecycleRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)